Advertisement
Canada markets close in 5 hours 26 minutes

  • S&P/TSX

    22,003.53
    +131.57 (+0.60%)
     

  • S&P 500

    5,066.58
    +55.98 (+1.12%)
     

  • DOW

    38,441.53
    +201.55 (+0.53%)
     

  • CAD/USD

    0.7322
    +0.0020 (+0.28%)
     

  • CRUDE OIL

    82.10
    +0.20 (+0.24%)
     

  • Bitcoin CAD

    91,359.77
    +629.97 (+0.69%)
     

  • CMC Crypto 200

    1,439.17
    +24.41 (+1.72%)
     

  • GOLD FUTURES

    2,337.80
    -8.60 (-0.37%)
     

  • RUSSELL 2000

    1,997.53
    +30.05 (+1.53%)
     

  • 10-Yr Bond

    4.5720
    -0.0510 (-1.10%)
     

  • NASDAQ

    15,685.56
    +234.25 (+1.52%)
     

  • VOLATILITY

    16.34
    -0.60 (-3.54%)
     

  • FTSE

    8,033.44
    +9.57 (+0.12%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Stocks in play: Medexus Pharmaceuticals

Baystreet.ca

Today announced that the American Journal of Hematology has accepted for publication the final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by medac, a strategic partner of Medexus. The publication has undergone full peer review and has already been published online. Medexus Pharmaceuticals shares T.MDP are trading up $0.11 at $2.18.

Read: